Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Squamous Cell Carcinoma of the Head and Neck – Unmet Need – Unmet Need – Recurrent or Metastatic Non-Nasopharyngeal Squamous Cell Carcinoma of Head and Neck (US/EU)
Recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck is an aggressive malignancy associated with a high recurrence rate. The approval of immune checkpoint…
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC (US/EU)
Approximately 20% of nonsquamous NSCLC in Western patients is driven by mutations in EGFR, and as such is treated predominantly with agents targeting those alterations. The market is currently…
Multiple Sclerosis – Access & Reimbursement – Access & Reimbursement – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market continues to evolve as each new approved disease-modifying therapy (DMT) further expands treatment choice. The most recent launches have entered…
Colorectal Cancer – Unmet Need – Unmet Need – Previously treated BRAF-mutant or RAS-mutant metastatic colorectal cancer (US/EU)
The treatment landscape for second- and later-line metastatic colorectal cancer with BRAF or RAS mutations is rapidly changing following the market entry of biomarker-specific combination therapies…
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and topical steroids. Although these therapies can alleviate EoE symptoms, their remission…
Axial Spondyloarthritis – Unmet Need – Unmet Need – Nonradiographic Axial Spondyloarthritis (US/EU)
TNF-alpha inhibitors, such as AbbVie’s Humira, Amgen’s Enbrel, Johnson & Johnson Innovative Medicine’s Simponi, and UCB’s Cimzia, are approved for the treatment of nonradiographic axial…
Non-Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Non-Small-Cell Lung Cancer (US)
Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. In 2024, Imfinzi…
Non-Small-Cell Lung Cancer – Current Treatment – Treatment Sequencing – Non-Small-Cell Lung Cancer (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
